compounded glp 1 going away Despite FDA ruling, GLP-1s are still giving Novo and Lilly headaches on the market sustainable wellness goals. Why the FDA is cracking

As Dr Breit explained, "GLP-1 RAs may have antidepressant and anti-anxiety effects, potentially due to their anti-inflammatory and anti-oxidative properties, which can also help reduce neuroinflammation." She adds: "This research provides much-needed evidence in support of GLP-1RAs to help safely address the burden of obesity in people with mental illness

Need help with weight loss

Lilly's oral GLP-1, orforglipron, delivers weight loss of up to an average of 27.3 lbs in first of two pivotal phase 3 trials in adults with obesity (ATTAIN-1)

Well also address a rare side effect called Paradoxical Adipose Hyperplasia (PAH) and the support available through the Allergan program

April 30, 2026: The bulks-list pathway is now proposed to be closed permanently